MedTrace Logo

Influenza Immunity in Children

NCT02559505 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2021-09-02

Study results available
· View outcomes & findings →

Summary

This study evaluates how different methods of early exposure to influenza (natural infection, live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate immunity and poise the immune system to respond to a future challenge with the inactivated influenza vaccine.

Conditions

Interventions

BIOLOGICAL

Seasonal IIV 0.25 mL dose

Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age

OTHER

Natural influenza infection

Children enrolled on presentation to their primary care provider with a natural influenza infection

BIOLOGICAL

Seasonal IIV 0.5 mL dose

Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Jennifer L Nayak, MD · University of Rochester

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Months
Max Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2020-07-03
Completion
2020-07-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02559505 on ClinicalTrials.gov